<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454986</url>
  </required_header>
  <id_info>
    <org_study_id>C11-002</org_study_id>
    <nct_id>NCT01454986</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of ALXN1007 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose
      of ALXN1007 in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be screened for eligibility after providing signed informed consent. Once a
      subject is determined to be eligible, the subject will be vaccinated with the quadrivalent
      meningococcal conjugate vaccine at least two weeks prior to dosing, if applicable. A total of
      7 dose cohorts will be enrolled sequentially and randomized to receive ALXN1007 or placebo.
      Subjects will receive ALXN1007 or placebo at the clinic and be kept at the clinic for a total
      of 4 days for observation and completion of the required study tests.

      The subjects will return for 8 additional clinic visits to complete the required study tests
      over the next 86 days. The total duration of the study is 90 days from the day of dosing with
      ALXN1007 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of a single dose of ALXN1007.</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Safety and tolerability of a single dose of ALXN1007 assessed by physical exam, vital signs, ECG, immunogenicity, lab analysis and adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALXN1007</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Estimate PK parameters of ALXN1007 using standard measures for these parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameters of ALXN1007</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Identify PD effects of ALXN1007 by assessing standard complement measures for these parameters.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.06 mg/kg ALXN1007</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg ALXN1007</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/kg ALXN1007</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mg/kg ALXN1007</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.0 mg/kg ALXN1007</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6.0 mg/kg ALXN1007</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10.0 mg/kg ALXN1007</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1007</intervention_name>
    <description>Single dose, IV</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose, IV</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals 25 to 55 years of age with documented vaccination with MCV4.

        Exclusion Criteria:

          -  Abnormal renal or liver function.

          -  History of meningococcal disease.

          -  History of Guillain-Barre syndrome.

          -  Known infection with HIV or Hepatitis B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PAREXEL Baltimore EPCU</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

